Prostate Nodule Smart Manager · Assessment, Follow-up & Treatment Decision — free guideline decision tool
This tool combines PI-RADS, PSA density, and DRE for biopsy/follow-up triage, then after diagnosis gives the NCCN risk-group name. Post-diagnosis treatment content is pending update and not shown.
Open guideline tool →Guideline-based
Implements the decision logic from published clinical guidelines.
Runs in your browser
No installation. Enter the patient's values and get a guideline recommendation instantly.
Data stays local
Nothing is uploaded. Results are for licensed clinicians only.
Worked calculation
The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.
| PI-RADS v2.1 category (mpMRI) | 3 |
|---|---|
| Serum PSA | 6.5 ng/mL |
| Prostate volume (for PSAD) | 50 mL |
| Digital rectal exam DRE | No nodule palpated |
| ISUP/grade group (if biopsied) | 2 (3+4) |
| Clinical stage cT (if diagnosed) | T2b |
→ConclusionPI-RADS 3 · diagnosed · risk group
- (1) Assessment & biopsy decision：PI-RADS 3 (equivocal). (PSAD ≈ 0.130 ng/mL/cc) PSAD < may follow up and defer biopsy.
- (2) Risk stratification：ISUP grade 2 / PSA < 10 / clinical stage t2b → NCCN unfavorable intermediate.
- (3) Post-diagnosis treatment (pending update)：Post-diagnosis treatment content is pending update to the current guidelines and is not shown; treat by risk group per the current version of the cited guidelines, with MDT decision.
| PI-RADS v2.1 category (mpMRI) | 1 |
|---|---|
| Serum PSA | 6.5 ng/mL |
| Prostate volume (for PSAD) | 50 mL |
| Digital rectal exam DRE | No nodule palpated |
| ISUP/grade group (if biopsied) | Not biopsied/unknown |
| Clinical stage cT (if diagnosed) | Unknown |
→ConclusionPI-RADS 1 · follow-up
- (1) Assessment & biopsy decision：PI-RADS 1: low probability of clinically significant cancer (csPCa). (PSAD ≈ 0.130 ng/mL/cc) PSAD < 0.15 and DRE negative → may defer biopsy, follow with PSA/MRI.
- Note：If biopsy-confirmed, entering ISUP grade, PSA, and clinical stage gives the NCCN risk-group name.
- Basis：PI-RADS v2.1 (ACR/ESUR 2019) + PSAD 0.15 consensus; NCCN prostate cancer Version 1.2027; EAU guideline; CSCO prostate cancer guideline.
Common questions
What is Prostate Nodule Smart Manager · Assessment, Follow-up & Treatment Decision?
This tool combines PI-RADS, PSA density, and DRE for biopsy/follow-up triage, then after diagnosis gives the NCCN risk-group name. Post-diagnosis treatment content is pending update and not shown.
How is Prostate Nodule Smart Manager · Assessment, Follow-up & Treatment Decision calculated? What is the core formula?
PI-RADS + PSAD (threshold 0.15) → biopsy decision. ISUP grade + PSA band + cT → NCCN risk group (low/favorable-int/unfavorable-int/high/very-high).
When is Prostate Nodule Smart Manager · Assessment, Follow-up & Treatment Decision used?
Use to decide biopsy versus follow-up (1–2 mostly follow-up, 3 by PSAD, 4–5 biopsy) and, once ISUP/stage are known, to name the risk group; treatment follows the current version of the cited guidelines.
What are the key clinical points for Prostate Nodule Smart Manager · Assessment, Follow-up & Treatment Decision?
PSAD < 0.15 with a negative DRE supports deferring biopsy at PI-RADS 1–3. Diagnosis relies on biopsy pathology, and the simplified risk stratification must integrate core involvement, PSAD, and genomics. After diagnosis, treat by NCCN risk group per the current version of the cited guidelines (pending update).
What are the limits and cautions when using Prostate Nodule Smart Manager · Assessment, Follow-up & Treatment Decision?
For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.
Does Prostate Nodule Smart Manager · Assessment, Follow-up & Treatment Decision upload patient data? Where is it calculated?
Calculation runs locally in the browser; inputs and results are not uploaded. For licensed clinicians only; interpret with history, investigations and local protocols — not a diagnosis or prescription.
How is Prostate Nodule Smart Manager · Assessment, Follow-up & Treatment Decision calculated in practice? Can you show a worked example?
Inputs: PI-RADS v2.1 category (mpMRI) 3, Serum PSA 6.5 ng/mL, Prostate volume (for PSAD) 50 mL, Digital rectal exam DRE No nodule palpated, ISUP/grade group (if biopsied) 2 (3+4), Clinical stage cT (if diagnosed) T2b → Result: Conclusion PI-RADS 3 · diagnosed · risk group（(1) Assessment & biopsy decision: PI-RADS 3 (equivocal). (PSAD ≈ 0.130 ng/mL/cc) PSAD < may follow up and defer biopsy., (2) Risk stratification: ISUP grade 2 / PSA < 10 / clinical stage t2b → NCCN unfavorable intermediate., (3) Post-diagnosis treatment (pending update): Post-diagnosis treatment content is pending update to the current guidelines and is not shown; treat by risk group per the current version of the cited guidelines, with MDT decision.） Inputs: PI-RADS v2.1 category (mpMRI) 1, Serum PSA 6.5 ng/mL, Prostate volume (for PSAD) 50 mL, Digital rectal exam DRE No nodule palpated, ISUP/grade group (if biopsied) Not biopsied/unknown, Clinical stage cT (if diagnosed) Unknown → Result: Conclusion PI-RADS 1 · follow-up（(1) Assessment & biopsy decision: PI-RADS 1: low probability of clinically significant cancer (csPCa). (PSAD ≈ 0.130 ng/mL/cc) PSAD < 0.15 and DRE negative → may defer biopsy, follow with PSA/MRI., Note: If biopsy-confirmed, entering ISUP grade, PSA, and clinical stage gives the NCCN risk-group name., Basis: PI-RADS v2.1 (ACR/ESUR 2019) + PSAD 0.15 consensus; NCCN prostate cancer Version 1.2027; EAU guideline; CSCO prostate cancer guideline.）
Run Prostate Nodule Smart Manager · Assessment, Follow-up & Treatment Decision now
This tool combines PI-RADS, PSA density, and DRE for biopsy/follow-up triage, then after diagnosis gives the NCCN risk-group name. Post-diagnosis treatment content is pending update and not shown.
Open guideline tool →For licensed clinicians. Not a substitute for clinical judgement.
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.